Previous Close | 3.1000 |
Open | 3.1000 |
Bid | 2.9500 |
Ask | 4.1000 |
Strike | 6.00 |
Expire Date | 2024-07-19 |
Day's Range | 3.1000 - 3.1000 |
Contract Range | N/A |
Volume | |
Open Interest | 57 |
Explore the financial dynamics and strategic clinical advancements as ACXP progresses with its Phase III trials.
Q1 2024 Acurx Pharmaceuticals Inc Earnings Call
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced the successful outcome of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of ibezapolstat for the treatment of C. difficile Infection into Phase 3 studies based on the recently completed Phase 2 clinical trial results.